Unknown

Dataset Information

0

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19.

ABSTRACT:

SUBMITTER: Zelek WM 

PROVIDER: S-EPMC7605181 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19.

Zelek Wioleta M WM   Cole Jade J   Ponsford Mark J MJ   Harrison Richard A RA   Schroeder Ben E BE   Webb Nicholas N   Jolles Stephen S   Fegan Christopher C   Morgan Matt M   Wise Matt P MP   Morgan B Paul BP  

American journal of respiratory and critical care medicine 20201101 9

Similar Datasets

Unknown Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy.
| S-EPMC7501834 | biostudies-literature
Transcriptomics Complement activation induces excessive T cell cytotoxicity in severe COVID-19
2021-06-08 | GSE175450 | GEO
Unknown Complement C3 inhibition in severe COVID-19 using compstatin AMY-101.
| S-EPMC9385148 | biostudies-literature
Unknown Complement C5 inhibition in early onset HELLP syndrome.
| S-EPMC12268036 | biostudies-literature
Unknown Structural basis for therapeutic inhibition of complement C5.
| S-EPMC5771465 | biostudies-literature
Unknown Anti-complement C5 therapy with eculizumab in three cases of critical COVID-19.
| S-EPMC7410014 | biostudies-literature
Unknown C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis.
| S-EPMC12015038 | biostudies-literature
Unknown Inhibition of cleavage of human complement component C5 and the R885H C5 variant by two distinct high affinity anti-C5 nanobodies.
| S-EPMC10374974 | biostudies-literature
Unknown Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5.
| S-EPMC7209288 | biostudies-literature
Unknown Complement dysregulation is associated with severe COVID-19 illness.
| S-EPMC9052917 | biostudies-literature